Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Kochi University100 enrolled

Overview

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Pancreatic Cancer Resectable

Interventions

gemcitabineDRUG

neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * radiologically resectable pancreatic cancer patients Exclusion Criteria: * a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease

Outcomes

Primary Outcomes

Investigating the Presence of Occult Metastatic Lesions Detected During Neoadjuvant Therapy.

Time frame: within 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.